Abbott Laboratories (ABT) Net Cash Flow (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Net Cash Flow data on file, last reported at -$1.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 53.07% year-over-year to -$1.7 billion; the trailing twelve-month figure through Mar 2026 stood at $247.0 million (down 13.03% YoY), and the FY2025 full-year result was $835.0 million, up 2.33% from the prior year.
• Net Cash Flow fell to -$1.7 billion in Q1 2026, from $1.0 billion in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $1.3 billion in Q2 2022 to a low of -$2.1 billion in Q1 2022.
• A 5-year average of -$164.9 million and a median of $162.0 million in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow sank 269.71% in 2022 and jumped 612.77% in 2025, its largest moves.
• Tracing ABT's Net Cash Flow over 5 years: stood at $237.0 million in 2022, then tumbled by 31.65% to $162.0 million in 2023, then declined by 12.96% to $141.0 million in 2024, then jumped by 612.77% to $1.0 billion in 2025, then sank by 268.76% to -$1.7 billion in 2026.
• Business Quant data shows ABT's Net Cash Flow at -$1.7 billion in Q1 2026, $1.0 billion in Q4 2025, and $570.0 million in Q3 2025.